Design Therapeutics Inc DSGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
4.61quote price arrow up+0.04 (+0.88%)
Volume
3,014
Close
4.57quote price arrow down-0.20 (-4.19%)
Volume
245,949
52 week range
1.94 - 8.47
Loading...
  • Open4.77
  • Day High4.89
  • Day Low4.57
  • Prev Close4.77
  • 52 Week High8.47
  • 52 Week High Date05/10/23
  • 52 Week Low1.94
  • 52 Week Low Date08/22/23

Key Stats

  • Market Cap258.182M
  • Shares Out56.50M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta1.93
  • YTD % Change72.45

KEY STATS

  • Open4.77
  • Day High4.89
  • Day Low4.57
  • Prev Close4.77
  • 52 Week High8.47
  • 52 Week High Date05/10/23
  • 52 Week Low1.94
  • 52 Week Low Date08/22/23
  • Market Cap258.182M
  • Shares Out56.50M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta1.93
  • YTD % Change72.45

RATIOS/PROFITABILITY

  • EPS (TTM)-1.05
  • P/E (TTM)-4.37
  • Fwd P/E (NTM)-4.50
  • EBITDA (TTM)-77.653M
  • ROE (TTM)-22.10%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Design Therapeutics Inc

 

Profile

MORE
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN...
Pratik Shah Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Sean Jeffries Ph.D.
Chief Operating Officer
Address
6005 Hidden Valley Road, Suite 110
Carlsbad, CA
92011
United States

Top Peers

SYMBOLLASTCHG%CHG
ABOS
Acumen Pharmaceuticals Inc
3.36-0.21-5.88%
PRLD
Prelude Therapeutics Inc
3.73-0.34-8.35%
TRVI
Trevi Therapeutics Inc
2.73-0.19-6.51%
ATOS
Atossa Therapeutics Inc
1.49-0.20-11.83%
GALT
Galectin Therapeutics Inc
3.03-0.22-6.77%